APRIL is a novel clinical chemo-resistance biomarker in colorectal adenocarcinoma identified by gene expression profiling

BACKGROUND: 5-Fluorouracil(5FU) and oral analogues, such as capecitabine, remain one of the most useful agents for the treatment of colorectal adenocarcinoma. Low toxicity and convenience of administration facilitate use, however clinical resistance is a major limitation. Investigation has failed to...

Descripción completa

Detalles Bibliográficos
Autores principales: Petty, Russell D, Samuel, Leslie M, Murray, Graeme I, MacDonald, Graham, O'Kelly, Terrence, Loudon, Malcolm, Binnie, Norman, Aly, Emad, McKinlay, Aileen, Wang, Weiguang, Gilbert, Fiona, Semple, Scot, Collie-Duguid, Elaina SR
Formato: Texto
Lenguaje:English
Publicado: BioMed Central 2009
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801520/
https://www.ncbi.nlm.nih.gov/pubmed/20003335
http://dx.doi.org/10.1186/1471-2407-9-434

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2801520/
https://www.ncbi.nlm.nih.gov/pubmed/20003335
http://dx.doi.org/10.1186/1471-2407-9-434

Ejemplares similares